Senior Medical Science Liaison- Cardiorenal Medical Affairs Bayer Pharmaceuticals
Insulin resistance has been associated with an increased risk of T2D, CV disease, and CKD. In this analysis, we investigated the association between insulin resistance and risk of cardiorenal outcomes using data from FIDELITY, a prespecified pooled dataset of the FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049) studies which investigated the safety and efficacy of finerenone in people with CKD and T2D. We also investigated whether insulin resistance modified the efficacy of finerenone in the pooled FIDELITY dataset. Estimated glucose disposal rate (eGDR) was used as an inverse marker of insulin resistance. Analysis by continuous eGDR demonstrated a significantly lower risk of CV events at 3.5 years with increasing eGDR. eGDR was not associated with kidney outcomes in patients. Finerenone efficacy and safety were also not modified by baseline insulin resistance.
